1	Routine Urinary Biochemistry Does Not Accurately Predict Stone Type Nor Recurrence in
2	Kidney Stone Formers: A Multi-Centre, Multi-Model, Externally Validated Machine-Learning
3 4	<u>Study</u>
5 6	Robert M Geraghty, Ian Wilson, Eric Olinger, Paul Cook, Susan Troup, David Kennedy, Alistair Rogers, Bhaskar K Somani, Nasser A Dhayat, Daniel G Fuster, John A Sayer
7	
8	Mr Robert Geraghty - Corresponding Author
9 10	Academic Clinical Fellow in Urology Department of Urology
10	Freeman Hospital
12	Newcastle-upon-Tyne
12	Rob.geraghty@newcastle.ac.uk
14	<u>Nov.SerdShry &amp; Newedsheldeldk</u>
15	Dr Eric Olinger
16	Post-Doctoral Researcher
17	Translational and Clinical Institute, Faculty of Medical Sciences, Newcastle University,
18	Central Parkway, Newcastle upon Tyne, England, United Kingdom.
19	
20	Dr Ian Wilson
21	Lecturer in Biomedical Statistics
22	Biosciences Institute
23	Newcastle University
24	International Centre for Life
25 26	Central Parkway
26 27	Newcastle-upon-Tyne
28	Dr Paul Cook
20 29	Consultant Chemical Pathologist
30	Department of Biochemistry
31	University Hospital Southampton
32	Southampton
33	
34	Ms Susan Troup
35	Principal Clinical Biochemist
36	Department of Biochemistry
37	Queen Elizabeth Hospital
38	Gateshead
39	
40	Dr David Kennedy
41 42	Consultant Clinical Biochemist
42 43	Department of Biochemistry Queen Elizabeth Hospital
43 44	Gateshead
44 45	Gutesneud
46	Mr Alistair Rogers
47	Consultant Urologist
	-

2

- 48 Department of Urology
- 49 Freeman Hospital
- 50 Newcastle-upon-Tyne
- 51
- 52 Professor Bhaskar Somani
- 53 Consultant Urologist and Professor of Urology
- 54 Department of Urology
- 55 University Hospital Southampton
- 56 Southampton
- 57
- 58 Dr Nasser Dhayat
- 59 Consultant Nephrologist
- 60 Department of Nephrology and Hypertension, Inselspital, Bern University Hospital,
- 61 University of Bern
- 62 Switzerland
- 63
- 64 Professor Daniel Fuster
- 65 Consultant Nephrologist and Associate Professor of Nephrology
- 66 Department of Nephrology and Hypertension, Inselspital, Bern University Hospital,
- 67 Department for Biomedical Research, University of Bern
- 68 Switzerland
- 69
- 70 Professor John Sayer
- 71 Professor of Nephrology and Honorary Consultant Renal Physician
- 72 Translational and Clinical Institute, Faculty of Medical Sciences, Newcastle University,
- 73 Central Parkway, Newcastle upon Tyne, England, United Kingdom.
- 74 The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Road, Newcastle upon
- 75 Tyne, England, United Kingdom.
- 76 National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle
- 77 upon Tyne, England, United Kingdom.
- 78
- 79 Keywords: Kidney stones, Machine learning, Prediction, Urinary Biochemistry
- 80

#### 81 Word Count:

- 82 Abstract: 271/300
- 83 Main body: 3574/4000
- 84 References:
- 85 Figures: 3
- 86 Tables: 3
- 87 Appendices: 3

### 88 <u>Abstract</u>

- 89 **Objectives:** Urinary biochemistry is used to detect and monitor conditions associated with
- 90 recurrent kidney stones. There are no predictive machine learning (ML) tools for kidney
- 91 stone type or recurrence. We therefore aimed to build and validate ML models for these
- 92 outcomes using age, gender, 24-hour urine biochemistry and stone composition.
- 93 Materials and Methods: Data from 3 cohorts were used, Southampton, UK (n=3013),
- 94 Newcastle, UK (n=5984) and Bern, Switzerland (n=794). Of these 3130 had available 24-hour
- 95 urine biochemistry measurements (calcium, oxalate, urate, pH, volume), and 1684 had
- 96 clinical data on kidney stone recurrence. Two predictive models were constructed (UK and
- 97 Swiss) using two ML techniques (Partitioning and Random Forests [RF]) and validated
- 98 internally with a subset of the same dataset (e.g UK model/UK test set), and externally with
- 99 the other dataset (UK model/Swiss test set).
- 100 **Results and Limitations:** For kidney stone type, on external validation accuracy of UK RF
- 101 model=0.79 (95% CI: 0.73-0.84), sensitivity: calcium oxalate=0.99 and calcium
- 102 phosphate/urate=0.00. Specificity: calcium oxalate=0.00 and calcium
- 103 phosphate/urate=0.99. For the Swiss RF model accuracy=0.87 (95% CI: 0.83-0.89),
- sensitivity: calcium oxalate=0.99 and calcium phosphate/urate=0.00. Specificity: calcium
- 105 oxalate=0.00, calcium phosphate=0.00 and urate=1.00.
- 106 For stone recurrence, on external validation accuracy of UK RF model=0.22 (95% CI:
- 107 0.19-0.25), sensitivity=0.93 and specificity=0.09. Swiss RF model accuracy=0.42 (95% CI:
- 108  $\,$  0.39-0.47), sensitivity=0.03 and specificity=0.97.
- 109 **Conclusions:** Neither kidney stone type nor kidney stone recurrence can be accurately
- $110 \qquad {\rm predicted\ using\ modelling\ tools\ built\ using\ specific\ 24-hour\ urinary\ biochemistry\ values}$
- 111 alone. Further studies to delineate accurate predictive tools should be undertaken using
- 112 both known and novel risk factors.

#### 113 Introduction

Kidney stones are prevalent<sup>1</sup>, costly<sup>2</sup> and debilitating, with a recurrence rate of around 40-50% at 10 years<sup>3</sup>. Although there are rare well described forms of kidney stones such as cystinuria leading to cystine stones, the pathophysiology underlying the most common types of kidney stones (calcium stones and urate) have not been satisfactorily described. Given the rising prevalence and cost of surgical treatment, tools are needed to accurately predict kidney stone type and more importantly, risk of recurrence so that preventative measures can be more focused and beneficial.

121 Kidney stone composition may not always be investigated, but remains vital for the 122 identification of rarer stone types that require further management. There has previously 123 been only one machine learning (ML) study that looked at prediction of kidney stone type<sup>4</sup>. 124 Several types of ML models were constructed for kidney stone type prediction, achieving 125 high accuracy (area under the curve (AUC)=0.99), although it was neither internally nor 126 externally validated. They did not use urinary biochemistry, instead utilising demographics 127 and basic medical history. Another study applied logistic regression to 24-hour urinary 128 biochemistries to predict stone type, but this demonstrated poor predictive value<sup>5</sup>.

129 Regression models are not as powerful as more modern ML techniques<sup>6</sup>.

130 The Recurrence of Kidney Stone (ROKS) nomogram was created to predict kidney 131 stone recurrence and is largely based on non-biochemical risk factors and radiologic 132 appearances, rather than biochemistry<sup>7</sup>. It had a moderate predictive value (AUC=0.65) for 133 kidney stone recurrence at 2-years on external validation<sup>8</sup>. Until accuracy improves, this 134 predictive model is not useful for influencing clinical practice.

135 Twenty four hour urine samples are often taken from high-risk stone formers<sup>9</sup> to 136 identify stone forming risk factors such as hyperoxaluria, hypercalciuria, hyperuricosuria etc. Although the benefit of urinary biochemistry for managing kidney stone patients has not 137 been fully established<sup>10</sup>, there is evidence from randomized controlled trials that 138 medications used in specific, limited circumstances reduce the number and increase the 139 time to, recurrence<sup>11</sup>. A systematic review by Hsi et al. delineates the limitations of 24-hour 140 141 urine collection, none of the included studies demonstrate any predictive value for recurrence<sup>10</sup>. 142

143To date there have been no predictive ML models for kidney stone type or144recurrence based on 24-hour urinary biochemistry. We therefore aimed to construct145predictive ML models for these outcomes using clinical and biochemical data from kidney146stone patients to assess the predictive value of 24-hour urinary biochemistry.

148 Methods

147

149

Data Collection across all Cohorts

Age, sex, kidney stone recurrence, stone type and 24-hour urinary biochemistry(free-choice diet).

Urinary biochemistry obtained: calcium (mmol/24 hour), oxalate (mmol/24 hour),
urate (mmol/24 hour), urine volume (L) and pH. Citrate (mmol/24 hour) was obtained from
the Newcastle and Bern cohorts.

Stone type was ascertained using Fourier Transform IR spectroscopy in all cohorts.
 Differentiation between calcium oxalate types (monohydrate/dihydrate) was not available
 in the Southampton/Newcastle cohorts and therefore not included in analysis.

- 158
- 159

160	
161	<u>Southampton, UK</u>
162	Study Population
163	The cohort consisted of patients with kidney stone disease presenting to University
164	Hospital Southampton, UK (tertiary referral hospital) referred for metabolic assessment
165	between 1990-2007. The initial cross-sectional study (n=2801) <sup>12</sup> and subsequent cohort
166	subset <sup>2</sup> have been described. During this period, stone formers were routinely referred
167	from across Hampshire, Isle of Wight and Dorset. The subset includes 1000 patients with
168	further information ascertained retrospectively using hospital/general practice electronic
169	records.
170	Patients who had no documentation (i.e no evidence of subsequent follow-
171	up/consultation, lived outside/have left Hampshire or no documentation on CHIE) were
172	excluded [see fig. 1].
173	
174	Ethical Approval
175	Ethical approval for this arm of the study was granted by the NHS Bristol Research
176	Ethics Committee (Rec ref: 18/SW/0185; IRAS ID: 240061).
177	
178	<u>Newcastle upon Tyne, UK</u>
179	Study Population
180	The cohort consisted of patients with kidney stone disease presenting to hospitals in
181	the north of England between 2013 and 2018 [Appendix 1]. These include: The Newcastle
182	upon Tyne Hospitals NHS Foundation Trust (Newcastle-upon-Tyne), James Cook University
183	Hospital (Middlesbrough), Sunderland Royal Hospital, Durham University Hospital, Queen
184	Elizabeth Hospital (Gateshead), Darlington Memorial Hospital, Cumberland Infirmary
185	(Carlisle) and Northumbria Hospitals Trust (Wansbeck, Hexham, Cramlington).
186	Data ascertained retrospectively using electronic hospital records. Urinary biochemistry
187	and stone type were obtained from the regional renal calculi processing unit (Queen Elizabeth
188	Hospital, Gateshead).
189	
190	Ethical Approval
191	This arm was registered as an audit (current patients of authors) with Newcastle-
192	upon-Tyne Hospitals NHS Foundation Trust (audit number: 10337).
193	
194	<u>Bern, Switzerland</u>
195	Study Population
196	Patients enrolled in the Bern Kidney Stone Registry (BKSR) were referred to the
197	Department of Nephrology and Hypertension, Inselspital, Bern University Hospital and
198	included kidney stone formers suffering at least one stone episode. This population has
199	previously been described in the literature $^{13}$ . Those <18 years were excluded.
200	
201	Ethical Approval
202	The BKSR adheres to the Declaration of Helsinki, was approved by the Ethical
203	Committee of the Kanton Bern (#95/06) and all patients provided written informed consent.
204	
205	<u>Definitions</u>

6

206 Stone recurrence was defined as subsequent stone surgery or acute presentation 207 following previous treatment/spontaneous passage. Presence of asymptomatic recurrence 208 on imaging was not available.

- 209 Low urine volume was defined as <1.5L/24 hour. Acid urine was defined as pH <5.5.
- 210 Biochemical abnormalities were defined as follows, as per local laboratory values: 211 hypercalciuria in women >6.2 mmol/24 hour and men >7.5 mmol/24 hour; hyperoxaluria in
- 212 women >0.32 mmol/24 hour, men >0.49 mmol/24 hour; hyperuricosuria as >4.46 mmol/24
- 213 hour and hypocitraturia as <0.6 mmol/24 hour.
- 214

Primary kidney stone type was defined as >50% of particular type.


215 216

Statistical Analysis

217 Analysis was performed in R (version no.4.0.2). For robustness, two machine learning 218 models were used: Partitioning (rpart[19]) and Random Forests (randomForest[20] and 219 missForest[21]) for both Stone Type and Recurrence. Missing data was accounted for with 220 values imputed from existing data (missForest). Variables included in both analyses: age, 221 sex, raw 24-hour urinary values (calcium, oxalate, urate, volume), pH and number of 222 biochemical abnormalities. Urinary citrate was excluded due to low numbers with 223 documented citrate. To investigate whether unbalanced data was driving discrimination, up-224 sampling of training data was used to create balanced training data sets using caret[22], 225 which were run through subsequent analyses.

226 Recurrence rate was excluded in stone type models as this would be unknown at 227 point of presentation. Stone type was included in the recurrence models. Those with 228 unclear stone type were excluded from the Stone Type models. Data was partitioned into 229 training (70% of total) and test (30%) datasets. Diagnostic accuracy statistics are presented 230 in the results section. Sample sizes were not calculated as an effect size was not being 231 calculated. For robustness, two models were used for each measure, and models were 232 constructed from two cohorts. Sensitivity analysis is represented by the second model 233 (random forests), and by the second dataset (Bern).

7



235 236 Figure 1. Flow diagram of patient selection/Inclusion. ML=Machine Learning, ST=Stone type,

237 Re=Recurrence.

#### 238 <u>Results</u>


239

Patient and Biochemistry Demographics

240 There were 3013 kidney stone patients in the Southampton/Newcastle combined 241 dataset [see table 1]. There were 2074 men (mean age 49±15 years) and 939 women (mean 242 age 49±17 years). Stone types were as follows: calcium oxalate (n=1476, 49%), calcium 243 phosphate (n=119, 4%), urate (n=89, n=3%), cystine (n=5, 0.2%), struvite (magnesium) 244 ammonium phosphate) (n=3, 0.1%) and no data (n=1321, 44%). Those with no data are 245 likely to have passed their stone/post treatment fragments (e.g. shockwave lithotripsy) 246 spontaneously. The stone was then not available for analysis. Of these 3013, 890 had 247 information on whether or not the patient had a kidney stone recurrence. Of these, 374 had 248 a recurrence (39%). The low numbers of patients with follow-up information are likely due 249 to the patient not accessing medical services following the initial stone episode, moving 250 away or dying.

There were 794 kidney stone patients in the Bern dataset, with 204 women (mean age 45±15 years) and 590 men (mean age 48±13 years). Stone types were as follows: calcium oxalate (n=598, 76%), calcium phosphate (n=81, 10%), urate (n=47, n=6%), cystine (n=16, 2%), struvite (n=6, 0.8%) and no data (n=40, 5.1%) [see fig 2]. All had follow-up data available for stone recurrence. There were 676 recurrences (85%).

Across all 3 datasets, 3130 patients had full data on urinary biochemistry. There were 631 (20.1%) patients who had no biochemical diagnoses, 1331 (42.5%) patients with a single diagnosis and 1668 (37.3%) with a combination of biochemical abnormalities.



259

260 Figure 2. Graphical representation of differences between cohorts and sexes. On top row,

261 from left to right: bar chart of number of patients in each sex, in each cohort by stone type;

262 boxplot of age for each sex per stone type; boxplot of 24-hour urinary calcium (mmol/24

263 hour) for each sex per stone type. Bottom row, from left to right: boxplot of urinary pH for

264 each sex per stone type; boxplot of 24-hour urinary oxalate (mmol/24 hour) for each sex per

stone type; boxplot of 24 hour urinary uric acid (mmol/24 hour) for each sex per stone type.

9


266	Of those with full data on urinary biochemistry, 1002 patients had data on kidney
267	stone recurrence. In total 688 (68.7%) had a recurrence. There were 272 (74.7%)
268	recurrences in those with no biochemical diagnosis, 258 (67.0%) with a single biochemical
269	risk factor and 163 (64.4%) in those with a combination [see appendices 2 & 3].
270	The Southampton dataset did not contain 24-hour urinary citrate measurements. In
271	the Newcastle & Bern datasets there were 45 and 121 patients, respectively, with
272	hypocitraturia. Recurrence data was available in 144 patients, with recurrence in 11/23
273	(Newcastle, 47.8%) and 109/121 (Bern, 90.0%), respectively.
274	Discordant primary kidney stope type and 24-hour urine biochemistry was seen in

Discordant primary kidney stone type and 24-hour urine biochemistry was seen in 103 patients (5% of known stone type). Cystine stones (n=21) and struvite stones (n=9) were not included in the appendices given their low numbers and alternative aetiologies.

277 Data on subsequent primary stone type was available in the Bern dataset for a

subset of those with a stone recurrence (n=188). Change in primary stone type from initial

episode was seen in 42 patients (22%): calcium oxalate (n=26, 18%), calcium phosphate
(n=10, 37%), urate (n=5, 38%), cystine (n=0, 0%), struvite (n=1, 100%) [Figure 3].



282 Figure 3. Bar chart showing percentage of subsequent stone type for each first stone type,

283 data from the Bern Cohort. CaOx=Calcium Oxalate, CaPo=Calcium Phosphate, Ur=Urate,

284 Cys=Cystine, Stru=Struvite

285

		Southampton	Newcastle	Combined Southampton & Newcastle	Bern
Тс	otal, n	2801	212	3013	794
	Female, n	818 (29%)	91 (43%)	939 (31%)	204 (26%)
Sex	Female, Age±SD	49±16	50±19	49±17	45±15
JEX	Male, n	1984 (71%)	121 (57%)	2073 (69%)	590 (74%)
	Male, Age±SD	49±14	48±16	49±15	48±13
	Calcium Oxalate, n (%)	1393 (50%)	83 (39%)	1476 (49%)	598 (75.9%
	Calcium Phosphate, n (%)	59 (2%)	60 (28%)	119 (4.0%)	81 (10.3%)
Stone Type	Urate, n (%)	55 (2%)	34 (16%)	89 (3.0%)	47 (6.0%)
	Cystine, n (%)	5 (0.2%)	0	5 (0.2%)	16 (2.0%)
	Struvite, n (%)	1 (0.04%)	2 (1%)	3 (0.1%)	6 (0.8%)
	No data, n (%)	1288 (46%)	33 (16%)	1321 (44%)	40 (5.1%)
Recurrence, n/total with data (%)		325/855 (38%)	49/111 (44%)	374/890 (39%)	676/794 (85.1%)

286 Table 1. Patient and Kidney Stone Demographics. Age in years.

#### 287 <u>Machine Learning Models:</u>

#### 288 <u>Stone Type</u>

289 The training group had n=3092 patients, n=2360 of which had immediate clearance on

- fluoroscopy. On internal validation (test set: n with outcome/total; n=1015/1326), the
- diagnostic accuracy statistics were: Random forests (RF) AUC=0.73, accuracy= 0.77 (95%
- 292 CI:0.74-0.79), sensitivity=0.27, specificity=0.94; Partitioning AUC=0.63, accuracy=0.71(95%
- 293 CI:0.69-0.74), sensitivity=0.22, specificity=0.89; Extreme Gradient Boosting (XGBoost)
- 294 AUC=0.75, accuracy=0.77 (95% CI:0.75-0.80), sensitivity=0.27, specificity=0.94; Logistic
- 295 Regression (LR) AUC=0.63, accuracy=0.76 (95% CI:0.73-0.78), sensitivity=0.12,
- specificity=0.97; Classical Neural Network (NN) AUC=0.74, accuracy=0.75 (95% CI:0.73-0.78),
- 297 sensitivity=0.23, specificity=0.94; Bayesian GeneralisedLinear Model (BGLM)
- 298 AUC=0.75, accuracy=0.77 (95% CI:0.75-0.80), sensitivity=0.29, specificity=0.94; Deep Neural
- 299 Network (DNN) Single-outcome model AUC=0.59, accuracy=0.77 (95% CI:0.75-0.79),
- 300 sensitivity=0.57, specificity=0.79; DNN Multiple-outcome model AUC=0.53,
- 301 accuracy=0.77 (95% CI:0.75-0.79), sensitivity=0.60, specificity=0.78 [see figure 2
- and supplementary table 2].

303 304 305 306 307 308 309 310 311 312 313 314	Two models were built to predict kidney stone type, partitioning and Random Forests (RF). Both models used all available 24 hour urinary biochemical data (volume, calcium, oxalate, urate and pH), age and sex. Citrate was excluded as the Southampton data did not have this. Due to missing values (as detailed above), some biochemical values were imputed. Up-sampling of rare stone data, while marginally improving classification into rare stone types, overall gave inferior classification, therefore simple training sets are reported. For the internally validated Southampton/Newcastle models, the partitioning model accuracy was 0.89 (95% CI: 0.85-0.91) and RF model accuracy was 0.90 (95% CI: 0.87-0.92) [see table 3]. For the internally validated Bern models, the partitioning model accuracy was 0.75 (95% CI: 0.69-0.81) and RF model was 0.81 (95% CI: 0.78-0.84).
315	None of the models were able to predict cystine/struvite stones.
316	Free DF we add to see a start and the second start and the start and the second start and the
317	Each RF model was externally validated using the other dataset. For the
318	Southampton/Newcastle model, validated with Bern data, the accuracy was 0.79 (95% CI:
319 320	0.73-0.84). The sensitivity for: calcium oxalate=0.99, calcium phosphate/urate=0.00. The specificity for: calcium oxalate=0.00 and calcium phosphate/urate=0.99.
321	For the Bern model, validated with Southampton/Newcastle data, the accuracy was
322	0.87 (95% CI: 0.83-0.89). The sensitivity for: calcium oxalate=0.99, calcium phosphate=0.00
323	and urate=0.04. The specificity for: calcium oxalate=0.02, calcium phosphate=0.99 and
324	urate=1.00.
325	Addition of citrate into the models with the Newcastle and Bern datasets did not
326	demonstrate any difference in accuracy, sensitivity or specificity for stone type. Increasing
327	the predominant stone type threshold for calcium phosphate stones to 90% did not increase
328	accuracy, sensitivity or specificity.

#### 12

## 329 <u>Recurrence</u>

Two models were used to predict recurrence (Partitioning and RF). Both models used
 all biochemistry previously described, age and sex. Biochemical value imputation as above.
 For the internally validated Southampton/Newcastle models, the partitioning model
 accuracy was 0.52 (95% CI: 0.45-0.60), correctly predicting 25/72 recurrences and 70/109

- without. The RF model accuracy was 0.55 (95% CI: 0.48-0.63), correctly predicting 25/72
   recurrences and 75/109 without [see Table 4].
- For the internally validated Bern models, the partitioning model accuracy was 0.85 (95% CI: 0.80-0.89), correctly predicting 201/212 recurrences, and 2/27 without. The RF model accuracy was 0.89 (95% CI: 0.84-0.93), correctly predicting 163/165 recurrences, and
- 339 1/19 without.

Recurrence	Southamptor Mod	-	Bern l	Model
	Partitioning	Random	Partitioning	Random
		Forests		Forests
Accuracy	0.52 (0.45-	0.55 (0.48-	0.85 (0.80-	0.89 (0.84-
(95% CI)	0.60)	0.63)	0.89)	0.93)
Sensitivity	0.64	0.69	0.07	0.05
Specificity	0.35	0.35	0.95	0.99
PPV	0.60	0.61	0.15	0.33
NPV	0.40	0.42	0.89	0.90
Detection Rate	0.39	0.41	0.008	0.005

340 Table 2. Descriptive statistics for Partitioning and Random Forests models predicting

recurrence. PPV=positive predictive value, NPV=negative predictive value. Test set=30% of
 same cohort

Each RF model was externally validated as above. The Southampton/Newcastle model, validated with Bern data, accuracy was 0.22 (95% CI: 0.19-0.25), sensitivity=0.93, specificity=0.09, correctly predicting 55/632 recurrences and 108/116 without.

The Bern model, validated with Southampton/Newcastle data, accuracy was 0.42 (95% CI: 0.39-0.47), sensitivity=0.03, specificity=0.97, correctly predicting 235/242 recurrences and 11/332 without.

Addition of citrate into the models with the Newcastle and Bern datasets did not
demonstrate any difference in accuracy, sensitivity or specificity for stone type. Increasing
the predominant stone type threshold for calcium phosphate stones to 90% did not increase
accuracy, sensitivity or specificity.

353

#### 354 <u>Discussion</u>

355This study utilised 24-hour urinary biochemistry data from kidney stone patients356attending three European tertiary referral centres to make two cohorts

357 (Southampton/Newcastle and Bern), used to construct internally validated machine learning

358 (ML) models for both kidney stone type and kidney stone recurrence. These models were

then externally validated on the other cohort. The recurrence models had very poor

accuracy, whilst the kidney stone type models demonstrated high overall accuracy. However

361 this is likely due to the high number of calcium oxalate kidney stones in our datasets

(reflected in the literature [23]), the diagnostic statistics demonstrate very poor predictivevalue for other stone types. In essence the models predict every stone as calcium oxalate.

The poor predictive value for both outcomes are important negative findings. The composition of most kidney stones is unknown (36% in this study and ≤85% in the literature[24]), and 24-hour urine collection is used to identify recurrent/high-risk stone formers who could be started on prophylaxis [11,12].

The main strengths of this study are the large cohort sizes, internal & external validation[19,20], multiple ML models (superior to regression analyses[8]) showing similar outcomes and consistent outcomes across both datasets.

371 There are several weaknesses with this study. Few of the Newcastle kidney stone 372 patient cohort had 24-hour urinary biochemical analysis available, and fewer (in both 373 datasets) had data on recurrence. This was addressed with imputation of missing data[21]. 374 Unfortunately, 24-hour urinary citrate was not available in the Southampton dataset, which 375 may bias our main results as hypocitraturia is an important risk factor for calcium-containing 376 kidney stones [25]. To investigate this both models were repeated with citrate included for 377 the Bern/Newcastle datasets, this did not demonstrate any improvement in diagnostic 378 statistics. The datasets did not include 24-hour urinary phosphate or sodium, both of which 379 influence the risk of stone formation [26]. Therefore, predictive value may be improved with 380 the addition of these variables. The stone type models could not predict struvite or cystine 381 stones. This is likely due to minimal numbers of these stones, thus underpowering the 382 model, and their alternative pathophysiology [27,28]. Although it is accepted that those with 383 cystinuria, are at high risk of recurrence[28].

384 The datasets differ in terms of stone types proportions, notably uric acid and calcium 385 phosphate stones. For instance, in the Southampton and Bern cohorts uric acid stones 386 represent 3.6% and 6% respectively, whilst in the Newcastle dataset 19% have these (10% of 387 total 5984 patients). Uric acid stones are associated with obesity/metabolic syndrome[29], 388 and this observation may represent rising levels in Newcastle compared to an historic 389 population (Southampton), or a contemporary European population (Bern). This could also 390 represent referral bias, e.g. in the Bern cohort referral rates for urate stones were 391 historically lower than present. As information on BMI or diabetes mellitus was not available 392 this limits the predictive value of the models to predict stone type.

393 Proportions of calcium phosphate stones are also different between datasets (2% in 394 Southampton, whilst 28% in Newcastle). This may be due to selection bias, as large numbers 395 of patients in the Newcastle set did not have urinary biochemistry available. This may also 396 be due to our definition of predominant stone type (i.e >50%). Pure calcium phosphate 397 stones (>90%) are associated with a specific phenotype (alkaline urine and hypocitraturia) 398 [30]. Increasing the cut-off for calcium phosphate stones to >90% did not demonstrate an 399 increase in predictive power for either stone type or recurrence. This may be due to the low 400 numbers with this stone type (UK: from 4% to 2.8%, Bern: 10.3% to 2.6%). This touches on 401 the wider issue of stone type interpretation. There are no guidelines on how to interpret 402 stone composition, nor are there consistent methods within the literature. It is well known 403 that stones can take many forms/compositions, but translation of these observations has 404 yet to reach everyday practice. Our use of a >50% cut-off was an attempt to use standard 405 laboratory outputs to improve model accessibility.

406 As well as differences in stone type, recurrence data also differed between datasets, 407 Bern had a far higher rate than the UK cohorts (which are similar to the literature[5]). This is 408 likely due to the selection of patients going to biochemical clinic/tertiary care and will likely

409 skew the results as these patients are not representative of the general stone forming 410 population. This is reflected in the recurrence models, the Bern model predict most as 411 recurrence, whilst the Southampton/Newcastle model predict most as no recurrence. 412 24-hour urinary biochemistry is touted as a good measure to identify urinary risk 413 factors for stone formation[11,12]. In certain circumstances this is true[15], however there 414 are a significant minority of recurrent kidney stone formers who have no biochemical 415 abnormalities (20% in these cohorts and similar to rates seen in other studies[14,31]). This 416 may be due to dietary influence on urinary biochemistry, with a random diet unpredictably 417 influencing the results[32]. Further, a small proportion of patients have discordant urinary 418 biochemistry and stone type (3.3% across these cohorts), which makes prediction of 419 unknown stone type unreliable. In summary, the main challenge to model accuracy was not 420 unbalanced data but a lack of factors that could provide effective discrimination. 421 There is a growing body of evidence that kidney stone disease is the common end 422 point of a heterogenous group of disorders that include environmental[33], dietary[34,35], 423 monogenic[36] and polygenic risk factors[37,38], whether in isolation or combination. 424 Therefore reliance on urinary biochemistry alone as a predictive tool, as this study 425 demonstrates, is inadvisable. This study, along with a recent study demonstrating the futility 426 of serum biochemistry (except calcium)[39], demonstrate that current practices[11,12] to 427 delineate risk of kidney stone recurrence do not work well. At least 15% of kidney stones 428 have a monogenic cause [36], with a significant proportion forming calcium stones [40]. It is 429 evident that a precision medicine approach is needed to differentiate the differing causes of 430 KSD, which may then be treated effectively [41]. 431 Future studies are needed to delineate an effective kidney stone screen based on 432 traditional risk factors in combination with kidney stone analysis, 24-hour urinary 433 biochemistry, monogenic screen and polygenic risk scoring. 434 Conclusion 435 Neither kidney stone type nor kidney stone recurrence can be accurately predicted

by 24-hour urinary biochemistry. Further studies to delineate an effective stone screenshould be undertaken.

438

## 439 Acknowledgements

Robert Geraghty is a National Institute for Health Research Academic Clinical Fellow.
Eric Olinger is supported by an Early Postdoc Mobility Stipendium of the Swiss National
Science Foundation and Kidney Research UK. John Sayer is funded by Kidney Research UK
and the Northern Counties Kidney Research Fund.

444 We would like to acknowledge Dr Valerie Walker for initiating the Southampton 445 stone database.

446


# 447 <u>References</u>

Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the National Health and
Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on
Cost and Prevalence of Urolithiasis in 2030. European Urology 2014;66:724–9.
doi:10.1016/j.eururo.2014.06.036.

450	[0]	Conservation DM Construction of the operation of the oper
452 453	[2]	Geraghty RM, Cook P, Walker V, Somani BK. Evaluation of the economic burden of
455 454		kidney stone disease in the UK: a retrospective cohort study with a mean follow-up
	[2]	of 19 years. BJU Int 2020;125:586–94. doi:10.1111/bju.14991. Lien C-S, Huang C-P, Chung C-J, Lin C-L, Chang C-H. Increased risk of anxiety among
455	[3]	
456		patients with urolithiasis: A nationwide population-based cohort study. Int J Urol
457	[ 4 ]	2015;22:937–42. doi:10.1111/iju.12865.
458	[4]	Canales BK, Sharma N, Yuzhakov SV, Bozorgmehri S, Otto BJ, Bird VG. Long-term
459		Recurrence Rates in Uric Acid Stone Formers With or Without Medical
460	[-1	Management. Urology 2019;131:46–52. doi:10.1016/j.urology.2019.05.023.
461	[5]	Ljunghall S, Danielson BG. A Prospective Study of Renal Stone Recurrences. British
462	101	Journal of Urology 1984;56:122-4. doi:10.1111/j.1464-410X.1984.tb05346.x.
463	[6]	Kazemi Y, Mirroshandel SA. A novel method for predicting kidney stone type using
464		ensemble learning. Artif Intell Med 2018;84:117–26.
465		doi:10.1016/j.artmed.2017.12.001.
466	[7]	Moreira DM, Friedlander JI, Hartman C, Elsamra SE, Smith AD, Okeke Z. Using 24-
467		hour urinalysis to predict stone type. J Urol 2013;190:2106–11.
468		doi:10.1016/j.juro.2013.05.115.
469	[8]	Boulesteix AL, Schmid M. Machine learning versus statistical modeling. Biometrical
470		Journal 2014;56:588–93. doi:10.1002/bimj.201300226.
471	[9]	Rule AD, Lieske JC, Li X, Melton LJ, Krambeck AE, Bergstralh EJ. The ROKS nomogram
472		for predicting a second symptomatic stone episode. J Am Soc Nephrol
473		2014;25:2878–86. doi:10.1681/ASN.2013091011.
474	[10]	Iremashvili V, Li S, Penniston KL, Best SL, Hedican SP, Nakada SY. External Validation
475		of the Recurrence of Kidney Stone Nomogram in a Surgical Cohort. J Endourol
476		2019;33:475–9. doi:10.1089/end.2018.0893.
477	[11]	Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU Guidelines on
478		Interventional Treatment for Urolithiasis. European Urology 2016;69:475–82.
479		doi:10.1016/j.eururo.2015.07.041.
480	[12]	Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, et al.
481		AUA Guidelines Medical Management of Kidney Stones: AUA Guideline. Juro
482		2014;192:316–24. doi:10.1016/j.juro.2014.05.006.
483	[13]	Eisner BH, Goldfarb DS. A Nomogram for the Prediction of Kidney Stone Recurrence.
484		Journal of the American Society of Nephrology 2014:1–3.
485		doi:10.1681/ASN.2013.111180.
486	[14]	Hsi RS, Sanford T, Goldfarb DS, Stoller ML. The Role of the 24-Hour Urine Collection
487		in the Prevention of Kidney Stone Recurrence. J Urol 2017;197:1084–9.
488		doi:10.1016/j.juro.2016.10.052.
489	[15]	Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical
490		management to prevent recurrent nephrolithiasis in adults: a systematic review for
491		an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535–
492		43.doi:10.7326/0003-4819-158-7-201304020-00005.
493	[16]	Walker V, Stansbridge EM, Griffin DG. Demography and biochemistry of 2800
494		patients from a renal stones clinic. Annals of Clinical Biochemistry 2013;50:127–39.
495		doi:10.1258/acb.2012.012122.
496	[17]	Dhayat NA, Lüthi D, Schneider L, Mattmann C, Vogt B, Fuster DG. Distinct
497		phenotype of kidney stone formers with renal phosphate leak. Nephrol Dial
498		Transplant 2019;34:129–37. doi:10.1093/ndt/gfy170.

<ul> <li>Vacual H+-ATPase B1 Subunit Polymorphism pE161K Associates with Impaired Urinary Acidification in Recurrent Stone Formers. J Am Soc Nephrol 2016;27:1544– 54. doi:10.1681/ASN.2015040367.</li> <li>Therneau TM, Atkinson B, Ripley MB. The rpart package 2010.</li> <li>Segal MR. Machine Learning Benchmarks and Random Forest Regression 2004.</li> <li>Stekhoven DJ. missForest: Nonparametric missing value imputation using random forest. Astrophysics Source Code Library n.d.:ascl:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library n.d.:ascl:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal Struite stones-pathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrune1.2014.99.</li> <li>Cillarion J, Fort-Liltös M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrune1.2014.99.</li> <li>Gragetty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bnjopen-2019-032094.</li> <li>Grases F, Co</li></ul>	499	[18]	Dhayat NA, Schaller A, Albano G, Poindexter J, Griffith C, Pasch A, et al. The
<ul> <li>Urinary Acidification in Recurrent Stone Formers. J Am Soc Nephrol 2016;27:1544– 54. doi:10.1681/ASN.2015040367.</li> <li>Therneau TM, Atkinson B, Ripley MB. The rpart package 2010.</li> <li>Segal MR. Machine Learning Benchmarks and Random Forest Regression 2004.</li> <li>Stekhoven DJ. missForest: Nonparametric missing value imputation using random forest. Astrophysics Source Code Library n.d.:asci:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library n.d.:asci:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisne BH, Sheth S, Dretler SP, Herrick R, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struxite stones-pathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font LJ Lidós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrueph.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic revive and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmiopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of r</li></ul>		[10]	
<ul> <li>54. doi:10.1681/ASN.2015040367.</li> <li>Therneau TM, Atkinson B, Ripley MB. The rpart package 2010.</li> <li>Segal MK. Machine Learning Benchmarks and Random Forest Regression 2004.</li> <li>Stekhoven DJ. missForest: Nonparametric missing value imputation using random forest. Astrophysics Source Code Library n.d.:ascl:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library n.d.:ascl:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/S00240-006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2012;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struwite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Litigó M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nruph.2010.69.</li> <li>Gragsty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmiopen-2019-032094.</li> <li>Gente DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;155:2214–4. doi:10.1016/s0002-5347(01)68203-3.</li> <li>Gentle DL, Stoller ML, Bruce</li></ul>			
<ul> <li>Therneau TM, Atkinson B, Ripley MB. The rpart package 2010.</li> <li>Segal MR. Machine Learning Benchmarks and Random Forest Regression 2004.</li> <li>Stekhoven DJ. missForest: Nonparametric missing value imputation using random forest. Astrophysics Source Code Library n.d.:ascl:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library n.d.:ascl:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney international 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:33–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Litijós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrurol.2016;90:2020;10:e032094. doi:10.1136/bnijopen-2019.032094.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bnijopen-2019.032094.</li> <li>Gertaghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and</li></ul>			
<ul> <li>Segal MR. Machine Learning Benchmarks and Random Forest Regression 2004.</li> <li>Stekhoven DJ. missForest: Nonparametric missing value imputation using random forest. Astrophysics Source Code Library. nd.:asci:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library nd.:asci:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.S002708.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.S002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Lilfós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrurol.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1138/s/bmipoen-2019.032094.</li> <li>Grases F, Costa-Bauzd A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micro</li></ul>		[19]	
<ul> <li>Stekhoven DJ. missForest: Nonparametric missing value imputation using random forest. Astrophysics Source Code Library n.d.:ascl:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library n.d.:ascl:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240.006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struute stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Liltjós M, Font J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:224–34. doi:10.1038/nrurol.2016.90.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Geragter DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0002-5347(01)68203</li></ul>			
<ul> <li>forest. Astrophysics Source Code Library n.d.:ascl:1505.011.</li> <li>Kuhn M. caret: Classification and Regression Training. Astrophysics Source Code Library n.d.:ascl:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick R, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/siki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Litijós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nreph.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of Kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0022 5347(01)68203 x.</li> <li>Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0029 5834(20)2063 3.</li> <li>Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;15</li></ul>	505	[21]	
<ul> <li>Library n.d.:ascl:1505.003.</li> <li>[23] Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>[24] Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>[25] Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Littjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nruepl.2010.059.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s002-5347(01)68203-x.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s002-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:</li></ul>			
<ul> <li>Library n.d.:ascl:1505.003.</li> <li>Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006- 0042-8.</li> <li>[24] Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>[25] Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Littjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrurol.2014.09.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8881(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0029-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone for</li></ul>	507	[22]	
<ul> <li>in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240-006-0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrupl.2014.99.</li> <li>Chillarón J, Font-Liltjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrupl.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen.2019.032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and tcialogy. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0002-5347(01)68203-x.</li> <li>Gutle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Gut G, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1039/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham:</li></ul>	508		Library n.d.:ascl:1505.003.
<ul> <li>in men and women. Urological Research 2006;34:193–9. doi:10.1007/s00240.006- 0042-8.</li> <li>Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Liltjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrueph.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen.2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0002-5347(01)68203-x.</li> <li>Gute DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62,</li></ul>	509	[23]	Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition
<ul> <li>[24] Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>[25] Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Litjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrureph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmijopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0002-8347(01)68203-x.</li> <li>[31] Gentle DL, Soller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s002-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrlor Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:</li></ul>	510		
<ul> <li>of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>[25] Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nruroh.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0002-5347(01)68203-x.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1039/ndt/gfaa60.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1007/978-3-030-15534-6_3.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry C</li></ul>			-
<ul> <li>of Urolithiasis in Japan: National Trends Between 1965 and 2005. Urology</li> <li>2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine</li> <li>composition in first-time and recurrent stone-formers. Urology 2012;80:776–9.</li> <li>doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney</li> <li>International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis,</li> <li>microbiology, and management strategies. Nat Rev Urol 2014;11:333–41.</li> <li>doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al.</li> <li>Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34.</li> <li>doi:10.1038/nrureh.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia</li> <li>increase the risk of kidney stone disease? results from a systematic review and</li> <li>meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of</li> <li>renal calculi closely related to their micromorphology and teilology. Clin Chim Acta</li> <li>2002;322:29–36. doi:10.1016/s0020-5347(01)68203-x.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro</li> <li>1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[33] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association</li> <li>of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion</li> <li>in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>Nutritional and Medical Management of Kidney Stones, vol.</li></ul>	512	[24]	Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics
<ul> <li>2008;71:209–13. doi:10.1016/j.urology.2007.09.034.</li> <li>Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrmeph.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>Garl Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s002-5347(01)68203 x.</li> <li>Fuster DG, Moorad GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1039/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3030.15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li></ul>	513		
<ul> <li>composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney international 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Liitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrneph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0029-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0029-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Gari</li></ul>	514		
<ul> <li>composition in first-time and recurrent stone-formers. Urology 2012;80:776–9. doi:10.1016/j.urology.2012.06.034.</li> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Liitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrureph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0029-5347(01)68203-x.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0029-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Gar</li></ul>	515	[25]	Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine
<ul> <li>[26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrneph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	516		composition in first-time and recurrent stone-formers. Urology 2012;80:776–9.
<ul> <li>International 2008;73:489–96. doi:10.1038/sj.ki.5002708.</li> <li>[27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41. doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrureph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	517		doi:10.1016/j.urology.2012.06.034.
<ul> <li>Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis, microbiology, and management strategies. Nat Rev Urol 2014;11:333–41.</li> <li>doi:10.1038/nrurol.2014.99.</li> <li>Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34.</li> <li>doi:10.1038/nrneph.2010.69.</li> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1039/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	518	[26]	Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney
<ul> <li>microbiology, and management strategies. Nat Rev Urol 2014;11:333–41.</li> <li>doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al.</li> <li>Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34.</li> <li>doi:10.1038/nrneph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia</li> <li>increase the risk of kidney stone disease? results from a systematic review and</li> <li>meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of</li> <li>renal calculi closely related to their micromorphology and etiology. Clin Chim Acta</li> <li>2002;322:29–36. doi:10.1016/s0029-8981(02)0063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro</li> <li>1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association</li> <li>of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion</li> <li>in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,</li> <li>Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	519		International 2008;73:489–96. doi:10.1038/sj.ki.5002708.
<ul> <li>doi:10.1038/nrurol.2014.99.</li> <li>[28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al.</li> <li>Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34.</li> <li>doi:10.1038/nrneph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia</li> <li>increase the risk of kidney stone disease? results from a systematic review and</li> <li>meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of</li> <li>renal calculi closely related to their micromorphology and etiology. Clin Chim Acta</li> <li>2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro</li> <li>1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association</li> <li>of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion</li> <li>in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,</li> <li>Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	520	[27]	Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stonespathogenesis,
<ul> <li>523 [28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrneph.2010.69.</li> <li>526 [29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>529 [30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>531 [31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>534 [32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>537 [33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>540 [34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	521		microbiology, and management strategies. Nat Rev Urol 2014;11:333–41.
<ul> <li>Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010;6:424–34. doi:10.1038/nrneph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>	522		doi:10.1038/nrurol.2014.99.
<ul> <li>doi:10.1038/nrneph.2010.69.</li> <li>[29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[28]	
<ul> <li>Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>increase the risk of kidney stone disease? results from a systematic review and meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>meta-analysis. BMJ Open 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.</li> <li>Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[29]	
<ul> <li>[30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>renal calculi closely related to their micromorphology and etiology. Clin Chim Acta 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>531 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.</li> <li>532 [31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>534 [32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>537 [33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>540 [34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[30]	
<ul> <li>[31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. Juro</li> <li>1997;158:2221-4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>[32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association</li> <li>of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion</li> <li>in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>[33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,</li> <li>Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>[34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>[35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>1997;158:2221-4. doi:10.1016/s0022-5347(01)68203-x.</li> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones. Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana, Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[31]	
535of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion536in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.537[33]538Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.538Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,539Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.540[34]541Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized541controlled trial of a low animal protein, high fiber diet in the prevention of recurrent542calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.543[35]Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,			
<ul> <li>in kidney stone formers. Nephrol Dial Transplant 2020. doi:10.1093/ndt/gfaa360.</li> <li>Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,</li> <li>Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[32]	
<ul> <li>537 [33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.</li> <li>538 Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,</li> <li>539 Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>540 [34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>541 controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>542 calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
538Nutritional and Medical Management of Kidney Stones, vol. 62, Cham: Humana,539Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.540[34]541Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized541controlled trial of a low animal protein, high fiber diet in the prevention of recurrent542calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.543[35]Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,			
<ul> <li>Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.</li> <li>Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[33]	
<ul> <li>540 [34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized</li> <li>541 controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>542 calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			
<ul> <li>541 controlled trial of a low animal protein, high fiber diet in the prevention of recurrent</li> <li>542 calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>			··· <b>=</b>
<ul> <li>542 calcium oxalate kidney stones. Am J Epidemiol 1996;144:25–33.</li> <li>543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,</li> </ul>		[34]	
543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,			
		Io - 1	
544 fluid, or supplements for secondary prevention of nephrolithiasis: a systematic		[35]	
	544		Tiuld, or supplements for secondary prevention of nephrolithiasis: a systematic

545		review and meta-analysis of randomized trials. European Urology 2009;56:72–80.
546		doi:10.1016/j.eururo.2009.03.031.
547	[36]	Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, et al. Fourteen
548		monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc
549		Nephrol 2015;26:543–51. doi:10.1681/ASN.2014040388.
550	[37]	Paranjpe I, Tsao N, Judy R, Paranjpe M, Chaudhary K, Klein D, et al. Derivation and
551		Validation of Genome Wide Polygenic Score for Urinary Tract Stone Diagnosis.
552		Kidney International 2020. doi:10.1016/j.kint.2020.04.055.
553	[38]	Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, et al. Genetic
554		variants of calcium and vitamin D metabolism in kidney stone disease. Nat Commun
555		2019;10:5175–10. doi:10.1038/s41467-019-13145-x.
556	[39]	Eyre KS, Lewis F, Cui H, Grout E, Mihai R, Turney BW, et al. Utility of blood tests in
557		screening for metabolic disorders in kidney stone disease. BJU Int 2020.
558		doi:10.1111/bju.15250.
559	[40]	Hill F, Sayer JA. Precision medicine in renal stone-formers. Urolithiasis 2019;47:99–
560		105. doi:10.1007/s00240-018-1091-5.
561	[41]	Sayer JA, Moochhala SH, Thomas DJ. The Medical Management of Urolithiasis:.
562		British Journal of Medical and Surgical Urology 2010;3:87–95.
563		doi:10.1016/j.bjmsu.2010.02.004.



565 566

564

Appendix 1. Study centre locations.

Southampton + Newcastle		Stone Type, n (% of Biochemical Diagnosis)				Recurrence, n/total n
24-hour urine finding	Total, n (%) (total n=2521)	Calcium Oxala te	Calcium Phosphate	Urate	Unknown	(total with data on Recurrence, n=391)
No abnormality	520 (20.6%)	256 (49.2%)	29 (5.6%)	7 (1.3%)	227 (43.7%)	40/95
Low Urine Volume	344 (13.6%)	166 (48.3%)	11 (3.2%)	3 (0.9%)	164 (47.7%)	21/53
Hypercalciuria	333 (13.2%)	169 (50.8%)	7 (2.1%)	3 (0.9%)	154 (46.2%)	19/39
Hyperoxaluria	172 (6.8%)	84 (48.8%)	4 (2.3%)	1 (0.6%)	81 (47.1%)	6/22
Acid urine	167 ( 6. 6%)	72 (43.1%)	2 (1.2%)	9 (5.4%)	84 (50.3%)	11/32
Hypercalciuria + Hyperoxaluria	134 (5.3%)	66 (49.3%)	5 (3.7%)	0	63 (47.0%)	6/17
Hypercalciuria + Low Urine Volume	128 (5.1%)	70 (54.7%)	2 (1.6%)	1 (0.8%)	55 (43.0%)	9/20
Acid urine + Low Urine Volume	121 (4.8%)	51 (42.1%)	0	11 (9. 1%)	59 (48.8%)	6/16
Hypercalciuria + Acid Urine	81 (3.2%)	35 (43.2%)	2 (2.5%)	1 (1.2%)	43 (53.1%)	1/4
Hyperoxaluria + Low Urine Volume	66 (2.6%)	38 (57.6%)	1 (1.5%)	0	27 (40.9%)	2/5
Hyperoxaluria + Acid Urine	47 (1.9%)	25 (53.2%)	1 (2.1%)	1 (2.1%)	20 (42.6%)	0/0
Hyperuricosuria	46 (1.8%)	25 (54.3%)	1 (2.2%)	2 (4.3%)	18 (39.1%)	3/10
Hypercalciuria + Hymenymiceoumic	46 (1.8%)	32 (69.6%)	0	0	14 (30.4%)	5/10
Hyperuricosuria Hyperoxaluria + Acid Urine + Low Urine Volume	33 (1.3%)	19 (57.6%)	0	2 (6.1%)	12 (36.4%)	2/7
Hypercalciuria + Hyperoxaluria +	30 (1.2%)	12 (40.0%)	0	1 (3.3%)	17 (56.7%)	4/9
Hyperuricosuria Hypercalciuria + Hyperoxaluria + Acid Urine	29 (1.2%)	15 (51.7%)	0	1 (3.4%)	13 (44.8%)	4/5
Hypercalciuria + Hyperoxaluria + Low Urine Volume	27 (1.1%)	17 (63.0%)	0	0	9 (33.3%)	1/1
Hypercalciuria + Acid Urine + Low Urine Volume	25 (1.0%)	13 (52.0%)	0	0	12 (48.0%)	2/2
Hyperuricosuria + Low Urine Volume	23 (0.9%)	8 (34.8%)	1 (4.3%)	2 (8.7%)	11 (47.8%)	1/2
Hyperuricosuria + Acid Urine	22 (0.9%)	9 (40.9%)	0	3 (13.6%)	10 (45.5%)	4/7
Hyperoxaluria + Hyperuricosuria Hypercalciuria	21 (0.8%)	11 (52.4%)	0	2 (9.5%)	8 (38.1%)	4/9
+ Hyperuricosuria + Low Urine Volume	19 (0.8%)	8 (42.1%)	0	0	11 (57.9%)	2/5
Hypercalciuria + Hyperuricosuria	18 (0.7%)	10 (55.6%)	0	1 (5.6%)	7 (38.9%)	2/5

20

+ Acid Urine						
Hyperuricosuria + Acid Urine + Low Urine Volume	13 (0.4%)	6 (46.2%)	0	4 (30.8%)	3 (23.1%)	2/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine	13 (0.4%)	6 (46.2%)	0	3 (23.1%)	4 (30.8%)	6/8
Hyperoxaluria + Hyperuricosuria + Low Urine Volume	10 (0.3%)	3 (30.0%)	1 (10.0%)	0	6 (60.0%)	1/1
Hyperoxaluria + Hyperuricosuria + Acid Urine	8 (0.3%)	4 (50.0%)	0	0	4 (50.0%)	0/1
Hypercalciuria + Hyperoxaluria + Acid Urine + Low Urine Volume	7 (0.2%)	3 (42.9%)	0	0	4 (57.1%)	0/2
Hypercalciuria + Hyperuricosuria + Acid Urine + Low Urine Volume	7 (0.2%)	3 (42.9%)	0	1 (14.3%)	3 42.9%)	2/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Low Urine Volume	6 (0.2%)	4 (66.7%)	0	0	2 (33.3%)	0/1
Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	4 (0.1%)	3 (75.0%)	0	0	1 (25.0%)	0/1
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	1 (0.0%)	1 (100.0%)	0	0	0	0/0

567

568 Appendix 2. Biochemistry diagnoses and recurrences for Newcastle/Southampton dataset.

2	1
4	-

Bern 24-hour urine finding	Total, n (%) (total n=609)	Stone Type, n (% of Biochemical Diagnosis)				Recurrence,
		Calcium Oxalate	Calcium Phosphate	Urate	Unknown	n/total n (total with data on Recurrence, n=609)
No abnormality	111 (18.2%)	85	13	3	3	97/111
Low Urine Volume	80 (13.1%)	65	5	3	4	66/80
Hypercalciuria	53 (8.7%)	43	7	0	2	46/53
Hyperoxaluria	78 (12.8%)	50	13	6	4	71/78
Acid urine	50 (8.2%)	36	2	6	4	41/50
Hypercalciuria + Hyperoxaluria	24 (3.9%)	19	4	0	1	23/24
Hypercalciuria + Low Urine Volume	12 (2.0%)	11	0	0	1	11/12
Acid urine + Low Urine Volume	31 (7.1%)	24	0	5	2	26/31
Hypercalciuria + Acid Urine	5 (0.8%)	5	0	0	0	4/5
Hyperoxaluria + Low Urine Volume	15 (2.5%)	12	0	1	2	11/15
Hyperoxaluria + Acid Urine	32 (5.3%)	26	3	1	2	25/32
Hyperuricosuria	8 (1.3%)	6	1	1	0	8/8
Hypercalciuria + Hyperuricosuria	15 (2.5%)	12	2	0	1	13/15
Hyperoxaluria + Acid Urine + Low Urine Volume	11 (1.8%)	8	0	3	0	11/11
Hypercalciuria + Hyperoxaluria + Hyperuricosuria	15 (2.5%)	11	2	0	2	14/15
Hypercalciuria + Hyperoxaluria + Acid Urine	9 (1.5%)	7	0	1	1	8/9
Hypercalciuria + Hyperoxaluria + Low Urine Volume	2 (0.3%)	2	0	o	0	2/2
Hypercalciuria + Acid Urine + Low Urine Volume	6 (1.0%)	5	0	1	0	5/6
Hyperuricosuria + Low Urine Volume	4 (0.7%)	4	0	0	0	3/4
Hyperuricosuria + Acid Urine	7 (1.1%)	5	2	0	0	5/7
Hyperoxaluria + Hyperuricosuria	11 (1.8%)	8	0	0	1	10/11
Hypercalciuria + Hyperuricosuria + Low Urine Volume	2 (0.3%)	1	1	0	0	2/2
Hypercalciuria + Hyperuricosuria + Acid Urine	7 (1.1%)	5	2	0	0	7/7
Hyperuricosuria + Acid Urine + Low Urine Volume	2 (0.3%)	2	0	0	0	2/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine	5 (0.8%)	4	1	0	0	4/5
Hyperoxaluria + Hyperuricosuria + Low Urine Volume	1 (0.2%)	1 ( 100%)	0	0	0	1/1

С	С
2	Z

Hyperoxaluria + Hyperuricosuria + Acid Urine	4 (0.7%)	3 (75%)	0	1 (25%)	0	4/4
Hypercalciuria + Hyperoxaluria + Acid Urine + Low Urine Volume	4 (0.7%)	3 (75%)	0	1 (25%)	0	4/4
Hypercalciuria + Hyperuricosuria + Acid Urine + Low Urine Volume	2 (0.3%)	1 (50%)	0	1 (50%)	0	1/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Low Urine Volume	1 (0.2%)	1 ( 100%)	0	0	0	1/1
Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	1 (0.2%)	1 ( 100%)	0	0	0	1/1
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	1 (0.2%)	1 ( 100%)	0	0	0	1/1

570

571 Appendix 3. Biochemistry diagnoses and recurrences for Bern database.